Q32 Bio (QTTB) Competitors $1.71 -0.18 (-9.52%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.05 (+3.22%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. CHRS, PLRX, JMAC, LXEO, IMUX, HURA, GALT, VTYX, DBVT, and ADVMShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include Coherus BioSciences (CHRS), Pliant Therapeutics (PLRX), Maxpro Capital Acquisition (JMAC), Lexeo Therapeutics (LXEO), Immunic (IMUX), TuHURA Biosciences (HURA), Galectin Therapeutics (GALT), Ventyx Biosciences (VTYX), DBV Technologies (DBVT), and Adverum Biotechnologies (ADVM). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. Coherus BioSciences Pliant Therapeutics Maxpro Capital Acquisition Lexeo Therapeutics Immunic TuHURA Biosciences Galectin Therapeutics Ventyx Biosciences DBV Technologies Adverum Biotechnologies Coherus BioSciences (NASDAQ:CHRS) and Q32 Bio (NASDAQ:QTTB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer CHRS or QTTB? Coherus BioSciences received 437 more outperform votes than Q32 Bio when rated by MarketBeat users. Likewise, 65.36% of users gave Coherus BioSciences an outperform vote while only 63.16% of users gave Q32 Bio an outperform vote. CompanyUnderperformOutperformCoherus BioSciencesOutperform Votes44965.36% Underperform Votes23834.64% Q32 BioOutperform Votes1263.16% Underperform Votes736.84% Do institutionals & insiders have more ownership in CHRS or QTTB? 72.8% of Coherus BioSciences shares are held by institutional investors. Comparatively, 31.3% of Q32 Bio shares are held by institutional investors. 7.6% of Coherus BioSciences shares are held by company insiders. Comparatively, 16.1% of Q32 Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is CHRS or QTTB more profitable? Q32 Bio has a net margin of 0.00% compared to Coherus BioSciences' net margin of -0.15%. Coherus BioSciences' return on equity of 0.00% beat Q32 Bio's return on equity.Company Net Margins Return on Equity Return on Assets Coherus BioSciences-0.15% N/A -24.44% Q32 Bio N/A -146.18%-54.49% Which has more volatility and risk, CHRS or QTTB? Coherus BioSciences has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Q32 Bio has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Which has higher valuation and earnings, CHRS or QTTB? Q32 Bio has lower revenue, but higher earnings than Coherus BioSciences. Q32 Bio is trading at a lower price-to-earnings ratio than Coherus BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCoherus BioSciences$266.96M0.36-$237.89M$0.194.41Q32 Bio-$6.65M-3.14-$112.96M-$10.37-0.16 Does the media refer more to CHRS or QTTB? In the previous week, Coherus BioSciences had 4 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for Coherus BioSciences and 1 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 1.87 beat Coherus BioSciences' score of 0.47 indicating that Q32 Bio is being referred to more favorably in the news media. Company Overall Sentiment Coherus BioSciences Neutral Q32 Bio Very Positive Do analysts prefer CHRS or QTTB? Coherus BioSciences currently has a consensus price target of $5.38, indicating a potential upside of 540.95%. Q32 Bio has a consensus price target of $24.71, indicating a potential upside of 1,345.28%. Given Q32 Bio's higher probable upside, analysts plainly believe Q32 Bio is more favorable than Coherus BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus BioSciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 SummaryCoherus BioSciences beats Q32 Bio on 12 of the 18 factors compared between the two stocks. Remove Ads Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.86M$6.92B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.00%P/E Ratio-0.127.2023.3318.68Price / Sales-3.14220.97388.4691.04Price / CashN/A65.6738.1634.64Price / Book0.086.396.894.23Net Income-$112.96M$142.12M$3.20B$247.15M7 Day Performance-17.39%-5.18%-3.02%-2.17%1 Month Performance-24.67%-7.49%1.63%-5.68%1 Year Performance-89.96%-8.78%9.74%-0.67% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.5958 of 5 stars$1.71-9.5%$24.71+1,345.3%N/A$20.86M$-6,651,000.00-0.1239Positive NewsCHRSCoherus BioSciences3.6017 of 5 stars$0.92-0.5%$5.38+487.0%-64.8%$106.12M$266.96M-11.45330PLRXPliant Therapeutics4.2853 of 5 stars$1.70+10.4%$13.31+683.1%-89.6%$104.10M$1.58M-0.5190Short Interest ↑High Trading VolumeJMACMaxpro Capital AcquisitionN/A$7.69-3.9%N/A+1,311.8%$103.26MN/A0.002,021LXEOLexeo Therapeutics3.3338 of 5 stars$3.11+1.3%$23.80+665.3%-73.1%$102.84M$650,000.00-0.9858Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageIMUXImmunic2.7885 of 5 stars$1.14-0.9%$12.67+1,011.1%-4.6%$102.69MN/A-0.9370Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHURATuHURA BiosciencesN/A$2.42+6.1%$13.00+437.2%N/A$102.33MN/A0.00N/AGALTGalectin Therapeutics1.6807 of 5 stars$1.61-4.2%$11.00+583.2%-30.3%$101.05MN/A-2.219Upcoming EarningsNews CoveragePositive NewsVTYXVentyx Biosciences2.1991 of 5 stars$1.41flat$10.00+609.2%-78.8%$100.29MN/A-0.6030Positive NewsDBVTDBV Technologies3.3745 of 5 stars$4.84-0.6%$22.50+364.9%-47.4%$99.55M$15.73M-1.0880Upcoming EarningsNews CoverageGap UpADVMAdverum Biotechnologies4.4138 of 5 stars$4.73+2.6%$27.83+488.4%-66.2%$98.39M$1M-0.79190Upcoming EarningsInsider TradeNews CoveragePositive News Remove Ads Related Companies and Tools Related Companies Coherus BioSciences Competitors Pliant Therapeutics Competitors Maxpro Capital Acquisition Competitors Lexeo Therapeutics Competitors Immunic Competitors TuHURA Biosciences Competitors Galectin Therapeutics Competitors Ventyx Biosciences Competitors DBV Technologies Competitors Adverum Biotechnologies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QTTB Stock Free QTTB Stock Alerts